Efficacy and Safety of a Novel Nanosomal Docetaxel Lipid Suspension as an Anticancer Agent - A Retrospective Study

Authors:

DOI: 10.23880/oajco-16000132

Volume 2, Issue 4

Abstract

This retrospective study evaluated the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS; DoceAqualip®) in advanced solid tumors. Medical charts of adults with solid tumors treated with DoceAqualip® (75-100mg/m2 IV q3week) at Noora Hospital between June 2014 and June 2016 were analyzed. Of 69 patients, 54% were men; majority had stages III (47.82%) and IV (31.88%) cancer; gastric adenocarcinoma was most common (34.8%) type. Efficacy data was available for 56 patients, which showed best overall response in 58.9% (BOR; complete response [CR, 12.5%] + partial response [PR, 46.4%], p

Keywords: DoceAqualip; NDLS; Docetaxel; G-CSF; Solid tumor

View PDF